Chatham, NJ – According to filings with the U.S. Securities and Exchange Commission, TruElastin Laboratories is raising $6,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Thomas Ford played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TruElastin Laboratories
TruElastin Laboratories is a pre-clinical stage medical device company that developed and patented a novel technique for crosslinking and stabilizing natural elastin. This technology platform has a wide range of clinical applications and is the basis of our clinical development program. Elastin is a critical material found naturally in the skin, joints, ligament, vascular system and the lungs. It provides tissues with elasticity, resiliency and suppleness. Despite being a desirable target for medical applications, creating a stable and useful form of elastin has been elusive. Until now. The first product candidate in our portfolio, TE219 was is designed as a longer-duration soft tissue filler for aesthetic applications.

To learn more about TruElastin Laboratories, visit http://truelastin.com/

Contact:
Thomas Ford, Chief Executive Officer
973-998-1119

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved